VIATRIS INC. Amortization
VIATRIS INC. (VTRS) reported Amortization of $579.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AdjustmentForAmortization · last filed 2026-08-06
- VIATRIS INC. amortization for the quarter ending 2026-06-30 was $579.30M, a 1.06% decline year-over-year.
- VIATRIS INC. amortization for the quarter ending 2026-03-31 was $584.60M, a 2.35% increase year-over-year.
- VIATRIS INC. amortization for the quarter ending 2025-12-31 was $673.60M, a 1.88% increase year-over-year.
- VIATRIS INC. amortization for the quarter ending 2025-09-30 was $593.40M, a 3.25% increase year-over-year.
- VIATRIS INC. amortization for fiscal 2025 was $2.42B, a 4.43% decline from fiscal 2024.
- VIATRIS INC. amortization for fiscal 2024 was $2.54B, a 7.96% increase from fiscal 2023.
- VIATRIS INC. amortization for fiscal 2023 was $2.35B, a 12.28% decline from fiscal 2022.
- VIATRIS INC. amortization for fiscal 2022 was $2.68B, a 4.52% decline from fiscal 2021.
| Period end | Amortization 3 month | Amortization 6 month | Amortization 9 month | Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $579.30M 10-Q · filed 2026-08-06 | $1.16B 10-Q · filed 2026-08-06 | $1.84B derived: sum of 3 quarters · filed 2026-08-06 | $2.43B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $584.60M 10-Q · filed 2026-05-07 | $1.26B derived: sum of 2 quarters · filed 2026-05-07 | $1.85B derived: sum of 3 quarters · filed 2026-05-07 | $2.44B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $673.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.27B derived: sum of 2 quarters · filed 2026-02-26 | $1.85B derived: sum of 3 quarters · filed 2026-08-06 | $2.42B 10-K · filed 2026-02-26 |
| 2025-09-30 | $593.40M 10-Q · filed 2025-11-06 | $1.18B derived: sum of 2 quarters · filed 2026-08-06 | $1.75B 10-Q · filed 2025-11-06 | $2.41B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $585.50M 10-Q · filed 2026-08-06 | $1.16B 10-Q · filed 2026-08-06 | $1.82B derived: sum of 3 quarters · filed 2026-08-06 | $2.39B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $571.20M 10-Q · filed 2026-05-07 | $1.23B derived: sum of 2 quarters · filed 2026-05-07 | $1.81B derived: sum of 3 quarters · filed 2026-05-07 | $2.51B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $661.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.24B derived: sum of 2 quarters · filed 2026-02-26 | $1.94B derived: sum of 3 quarters · filed 2026-02-26 | $2.54B 10-K · filed 2026-02-26 |
| 2024-09-30 | $574.70M 10-Q · filed 2025-11-06 | $1.27B derived: sum of 2 quarters · filed 2025-11-06 | $1.87B 10-Q · filed 2025-11-06 | $2.41B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $699.20M 10-Q · filed 2025-08-07 | $1.30B 10-Q · filed 2025-08-07 | $1.84B derived: sum of 3 quarters · filed 2026-02-26 | $2.42B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $601.00M 10-Q · filed 2025-05-08 | $1.14B derived: sum of 2 quarters · filed 2026-02-26 | $1.72B derived: sum of 3 quarters · filed 2026-02-26 | $2.31B derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $538.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.12B derived: sum of 2 quarters · filed 2026-02-26 | $1.71B derived: sum of 3 quarters · filed 2026-02-26 | $2.35B 10-K · filed 2026-02-26 |
| 2023-09-30 | $584.00M 10-Q · filed 2024-11-07 | $1.18B derived: sum of 2 quarters · filed 2024-11-07 | $1.81B 10-Q · filed 2024-11-07 | $2.59B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $591.20M 10-Q · filed 2024-08-08 | $1.23B 10-Q · filed 2024-08-08 | $2.01B derived: sum of 3 quarters · filed 2025-02-27 | $2.62B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $635.30M 10-Q · filed 2024-05-09 | $1.42B derived: sum of 2 quarters · filed 2025-02-27 | $2.03B derived: sum of 3 quarters · filed 2025-02-27 | $2.67B derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $780.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.40B derived: sum of 2 quarters · filed 2025-02-27 | $2.03B derived: sum of 3 quarters · filed 2025-02-27 | $2.68B 10-K · filed 2025-02-27 |
| 2022-09-30 | $615.90M 10-Q · filed 2023-11-08 | $1.25B derived: sum of 2 quarters · filed 2023-11-08 | $1.90B 10-Q · filed 2023-11-08 | $2.58B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $634.10M 10-Q · filed 2023-08-07 | $1.28B 10-Q · filed 2023-08-07 | $1.97B derived: sum of 3 quarters · filed 2024-02-28 | $2.64B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $648.10M 10-Q · filed 2023-05-08 | $1.33B derived: sum of 2 quarters · filed 2024-02-28 | $2.00B derived: sum of 3 quarters · filed 2024-02-28 | $2.69B derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $684.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.36B derived: sum of 2 quarters · filed 2024-02-28 | $2.04B derived: sum of 3 quarters · filed 2024-02-28 | $2.81B 10-K · filed 2024-02-28 |
| 2021-09-30 | $671.50M 10-Q · filed 2022-11-07 | $1.35B derived: sum of 2 quarters · filed 2022-11-07 | $2.12B 10-Q · filed 2022-11-07 | $2.74B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $681.60M 10-Q · filed 2022-08-08 | $1.45B 10-Q · filed 2022-08-08 | $2.07B derived: sum of 3 quarters · filed 2023-02-27 | $2.43B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $767.80M 10-Q · filed 2022-05-09 | $1.39B derived: sum of 2 quarters · filed 2023-02-27 | $1.75B derived: sum of 3 quarters · filed 2023-02-27 | $2.10B derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $617.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $985.40M derived: sum of 2 quarters · filed 2023-02-27 | $1.34B derived: sum of 3 quarters · filed 2023-02-27 | $1.69B 10-K · filed 2023-02-27 |
| 2020-09-30 | $368.10M 10-Q · filed 2021-11-08 | $719.70M derived: sum of 2 quarters · filed 2021-11-08 | $1.07B 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $351.60M 10-Q · filed 2021-08-09 | $702.80M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $351.20M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $1.76B 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $1.83B 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |